- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Drug Price Forecast Projects 4.57% Increase in 2020 Hospital Drug Spending
Vizient, Inc. announced the release of its July 2019 Drug Price Forecast. The forecast projects that health systems-including inpatient and non-acute environments-can expect a 4.57% increase for pharmaceutical purchases made from Jan. 1, 2020 to Dec. 31, 2020. The forecast also includes projections for specialty pharmacy and pediatric-specific medications.
Highlights from the forecast report include:
- Specialty drug price inflation is predicted to be 4.23%
- The composition of the U.S. biosimilars market could change dramatically in the very near future
- Drug shortages compromise patient care and contribute to higher costs, both direct and indirect
- Providers treating leukemia patients will experience higher costs as the standard of care shifts to new therapy combinations
- Supply challenges in the Immune globulin intravenous (IgIV) market will continue and prices are expected to steadily rise
The forecast can be accessed here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
